{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-000362","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2023-01-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.180332+00:00","generated_at":"2026-06-20T13:04:48.734652+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kala Pharma enters $40M ATM equity facility with Jefferies, prepays $10M Oxford loan","bullets":["New Open Market Sale Agreement with Jefferies for up to $40M in common stock at market prices; Jefferies gets up to 3% commission.","Prior $75M ATM facility fully utilized (565,974 shares sold for $75M gross proceeds); terminated Jan 10, 2023.","Company notified Oxford Finance of intent to prepay $5M by June 30, 2023 and $5M by Jan 31, 2024, reducing loan principal to ~$34M.","Prepayments include final payment fees and accrued interest; scheduled for Feb 2, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-000362","json":"https://secwatch.observer/filing/0001558370-23-000362.json","markdown":"https://secwatch.observer/filing/0001558370-23-000362.md","text":"https://secwatch.observer/filing/0001558370-23-000362.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837023000362/0001558370-23-000362-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837023000362/kala-20230118x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T13:04:48.734652+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"907b6340b019984ac5ebd8eb4276ba034f3e48c3","claim":"KALA BIO, Inc. entered into Open Market Sale Agreement with Jefferies LLC valued at $40,000,000 (effective 2023-01-19).","evidence_excerpt":"On January 19, 2023, Kala Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), entered into an Open Market Sale Agreement SM (the “ Sales Agreement ”) with Jefferies LLC, as agent (“ Jefferies ”), pursuant to which the Company may offer and sell shares of its common stock, $0.001 par value per share (the “ Common Stock ”), from time to time through Jefferies.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837023000362/0001558370-23-000362-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Value","value":"$40,000,000"},{"label":"Effective","value":"2023-01-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}